[go: up one dir, main page]

MX2009008994A - Composicion farmaceutica para la prevencion o tratamiento de enfermedades asociadas con la reduccion de lagrimas. - Google Patents

Composicion farmaceutica para la prevencion o tratamiento de enfermedades asociadas con la reduccion de lagrimas.

Info

Publication number
MX2009008994A
MX2009008994A MX2009008994A MX2009008994A MX2009008994A MX 2009008994 A MX2009008994 A MX 2009008994A MX 2009008994 A MX2009008994 A MX 2009008994A MX 2009008994 A MX2009008994 A MX 2009008994A MX 2009008994 A MX2009008994 A MX 2009008994A
Authority
MX
Mexico
Prior art keywords
carbon atom
prevention
pharmaceutical composition
treatment
disease associated
Prior art date
Application number
MX2009008994A
Other languages
English (en)
Inventor
Mamoru Kobayashi
Tetsuya Asari
Mariko Tadachi
Original Assignee
Kissei Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical filed Critical Kissei Pharmaceutical
Publication of MX2009008994A publication Critical patent/MX2009008994A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4453Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporciona una composición farmacéutica para la prevención o tratamiento de una enfermedad asociada con la reducción en las lágrimas. Se describe una composición farmacéutica para la prevención o tratamiento de una enfermedad asociada con la reducción de las lágrimas (ojos secos, queratoconjuntivitis sicca, enfermedad del epitelio de la córnea, alacrima, xeroftalmia, ojos secos relacionados con la edad, enfermedades de los ojos en el síndrome de Stevens-Johnson, enfermedad de los ojos en el síndrome de Sjögren, una úlcera de la córnea/conjuntival, resequedad durante el uso de lentes de contacto), la cual comprende derivados de amida de ácido feniletanolaminotetralincarboxílico representado por la fórmula general (I), o una sal farmacológicamente aceptable del mismo o similares como ingrediente activo. (I) en donde A representa un grupo alquileno inferior, B representa un grupo amino, un grupo di-alquilamino inferior, o un grupo amino alicíclico de 3 a 7 miembros el cual puede tener un átomo de oxígeno en el anillo, un átomo de carbono marcado con un asterisco "*" representa un átomo de carbono que tiene una configuración R- o S-, o un átomo de carbono que tiene una configuración R/S mezclada; y un átomo de carbono marcado con (S) representa un átomo de carbono que tiene una configuración-S.
MX2009008994A 2007-02-21 2008-02-20 Composicion farmaceutica para la prevencion o tratamiento de enfermedades asociadas con la reduccion de lagrimas. MX2009008994A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007040191 2007-02-21
PCT/JP2008/052814 WO2008102790A1 (ja) 2007-02-21 2008-02-20 涙液の減少に伴う疾患の予防または治療用医薬組成物

Publications (1)

Publication Number Publication Date
MX2009008994A true MX2009008994A (es) 2009-09-03

Family

ID=39710064

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009008994A MX2009008994A (es) 2007-02-21 2008-02-20 Composicion farmaceutica para la prevencion o tratamiento de enfermedades asociadas con la reduccion de lagrimas.

Country Status (8)

Country Link
US (1) US20110092509A1 (es)
EP (1) EP2123268A1 (es)
JP (1) JPWO2008102790A1 (es)
AU (1) AU2008218028A1 (es)
BR (1) BRPI0807715A2 (es)
CA (1) CA2677582A1 (es)
MX (1) MX2009008994A (es)
WO (1) WO2008102790A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG55296A1 (en) 1996-04-12 1998-12-21 Kissei Pharmaceutical Phenylethalolaminotetralincarboxamide derivatives
WO2001041806A1 (en) 1999-12-07 2001-06-14 Rohto Pharmaceutical Co., Ltd. Ophthalmic compositions
CA2619445A1 (en) * 2005-08-29 2007-03-08 Kissei Pharmaceutical Co., Ltd. Preventive or therapeutic agent for disease caused by decrease in lacrimal fluid

Also Published As

Publication number Publication date
EP2123268A1 (en) 2009-11-25
US20110092509A1 (en) 2011-04-21
JPWO2008102790A1 (ja) 2010-05-27
WO2008102790A1 (ja) 2008-08-28
CA2677582A1 (en) 2008-08-28
BRPI0807715A2 (pt) 2014-06-03
AU2008218028A1 (en) 2008-08-28

Similar Documents

Publication Publication Date Title
Sturdivant et al. Discovery of the ROCK inhibitor netarsudil for the treatment of open-angle glaucoma
WO2010004435A3 (en) Ph specific solutions of sodium mycophenolic acid for the treatment of eye disorders
US20120238623A1 (en) Inflammation and Autoimmune Disorder Treatment using RARa Selective Agonists
EA027828B1 (ru) Противовирусные соединения
JP2001511806A (ja) 神経栄養性スルホンアミド化合物の使用方法
US20110275693A1 (en) Pharmaceutical Compositions Comprising 2-Oxo-1-Pyrrolidine Derivatives
EA201270505A1 (ru) Производные иминотиадиазиндиоксида в качестве ингибиторов bace, композиции на их основе, и их применение
WO2011159550A3 (en) Lysophosphatidic acid receptor antagonist and uses thereof
US10822301B2 (en) 3-carbon substituted 4-aminocyclopent-1-ene-1-carboxylic acid compounds as inhibitors of gamma-aminobutyric acid (GABA) aminotransferase
RU2014122858A (ru) Лечение когнитивных расстройств (r)-7-хлор-n-(хинуклидин-3-ил)бензо[в]тиофен-2-карбосамидом и его фармацевтически приемлемыми солями
WO2007012064A2 (en) Prevention and treatment of hearing disorders
TN2009000253A1 (en) Solid dispersion of a neurokinin antagonist
CN102066402B (zh) 肽衍生物以及含有肽衍生物的用于促进泪液分泌的组合物
WO2024100452A3 (en) Heterocyclic compounds as sting agonists
MX2012001160A (es) Agonistas del receptor de esfingosina-1-fosfato.
MX2009007040A (es) Derivados de mononitrato de isosorbida para el tratamiento de hipertension ocular.
JP2003508512A (ja) 非ペプチド性サイクロフィリン結合化合物とその用途
US20080261984A1 (en) Use of S,S-Reboxetine in the Treatment of Pain
HRP20120231T1 (hr) Upotreba derivata indola kao aktivatora nurr-1 u liječenju parkinsonove bolesti
MX2009008994A (es) Composicion farmaceutica para la prevencion o tratamiento de enfermedades asociadas con la reduccion de lagrimas.
US20110263642A1 (en) Methods for treatment of multiple sclerosis
US10434097B1 (en) Methods and compositions for treating hearing disorders
CA2805371C (en) Therapeutic agent or prophylactic agent for neuropathic pain
EP1935417A4 (en) COMPOSITION FOR USE IN PREVENTING A HYPOGLYCEMIC STATE
RU2013126056A (ru) Композиция для лечения нарушений иннерваций (варианты)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal